Brian Keel — Billing Profile & Reimbursement Data
NPI 1720065394 · Newport News, VA · Ophthalmology Physician
Customize your policy alerts
Sign up for Brian Keel — Billing Profile & Reimbursement Data policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Brian Keel is a ophthalmology physician provider located in Newport News, Virginia. This profile covers 16 Medicare and 0 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Brian Keel |
| Address | 11800 Rock Landing Dr |
| City | Newport News |
| State | VA |
| ZIP | 23606 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | December 27, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.7M |
| Medicaid | $0 |
Key Findings
This provider’s billing profile is effectively single-payer: Total Medicare revenue is $2.7M and there is no Medicaid billing on file, so all reported public-payer activity is Medicare-driven. Analysts should treat Medicare as the material payer when assessing scale, utilization, and competitive position for this NPI.
Revenue is highly concentrated in a small set of intravitreal drug codes: the precomputed top 3 Medicare codes account for 86.7% of the provider’s Medicare revenue. The largest single contributor is J0178 ($1.5M, 57.0%), followed by J2777 ($584.6K, 21.6%) and J2778 ($215.7K, 8.0%), indicating most revenue flows from injectable retinal therapies.
Clinical/service-line mix is retina- and injection-centric: the dominant codes J0178, J2777, and J2778 are anti-VEGF and related intravitreal injections used to treat retinal disease, and 67028 (1.6K claims, $146.8K, 5.4%) further documents high-volume isolated intravitreal procedures. High utilization of 92134 (2.1K claims, $65.2K, 2.4%) — which ranks #949 of 26868 providers nationally at the 96th percentile and is described as notably above typical national volume — supports that the practice pairs frequent OCT imaging with injection management.
Competitive standing on the main drug codes is above median but not dominant nationally: J0178 ranks #414 of 3204 providers (87th percentile; typical, unremarkable volume for this code), J2777 ranks #521 of 2039 (74th percentile; typical, unremarkable volume), and J2778 ranks #364 of 1208 (70th percentile; typical, unremarkable volume). These positions signal the provider is a meaningful regional participant in intravitreal therapy but not a national outlier or market leader for these specific agents.
Operational mix includes routine outpatient follow-up visits and diagnostics but these generate a small share of revenue relative to drugs: 99213 (270 claims, $17.6K, 0.6%) ranks #68762 of 457151 providers (85th percentile; typical, unremarkable volume) while 92014 (485 claims, $41.2K, 1.5%) ranks #5627 of 35415 providers (84th percentile; typical, unremarkable volume). That pattern is consistent with a practice model where drug administration drives revenue and E/M and exam codes primarily support ongoing management.
There is limited use of low-cost compounded agents: J9035 (bevacizumab) appears only 26 times for $1.2K in revenue and ranks #1732 of 1852 providers (6th percentile; typical, unremarkable volume), suggesting preference or billing patterns toward branded, higher-reimbursed intravitreal agents. Dexamethasone implant J7312 is present at moderate volume (245 claims, $38.7K) and ranks #238 of 492 providers (50th percentile), indicating a mix that includes steroid implants alongside anti-VEGF therapies.
Surgical retina procedures are performed but at low frequency: 67036 (16 claims, $9.3K, 0.3%) and 67041 (11 claims, $9.9K, 0.4%) show occasional vitrectomy/retinal surgery activity and rank in modest national positions (#500 of 832 and #423 of 461 respectively), implying the provider primarily delivers office-based injections with occasional operative care. These small surgical volumes align with a predominantly ambulatory injection practice that retains some capability to perform or bill for retinal procedures.
The NPI tenure provides context for experience and market presence: this NPI was enumerated on 2005-12-27 (~21 years ago), indicating long-standing participation in Medicare which can reflect established referral relationships and sustained referral volume for retinal injections. Tenure combined with the concentrated revenue profile suggests an experienced, injection-focused ophthalmology practice with stable Medicare-driven demand.
Medicare: Total Revenue Breakdown by CPT/HCPCS Code
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
Medicare: Complete Services Breakdown
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,250 | $680 | $1.5M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 20,160 | $30 | $584.6K |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,210 | $180 | $215.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,560 | $90 | $146.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,100 | $30 | $65.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 490 | $90 | $41.2K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 250 | $160 | $38.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 270 | $70 | $17.6K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 220 | $60 | $13.7K |
| 67041 | In this procedure, the provider removes scar tissue from the retinal membrane that obscures vision. He removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical… | 10 | $900 | $9.9K |
Showing 1–10 of 16
Medicare: Competitive Analysis & Benchmarks
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
16 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 25 | 80 | 1,400 | $690 | $1.1M |
| J2777 | 20 | 60 | 13,200 | $30 | $517.1K |
| J2778 | 8 | 40 | 560 | $180 | $171.5K |
| 67028 | 29 | 90 | 1,000 | $90 | $107.1K |
| J7312 | 10 | 20 | 240 | $160 | $42.5K |
| 92014 | 203 | 870 | 170 | $80 | $32.8K |
| 67041 | 14 | 20 | 20 | $1,110 | $23.3K |
| J9035 | 54 | 60 | 170 | $50 | $19.9K |
| 67036 | 9 | 20 | 20 | $940 | $19.8K |
| 67210 | 10 | 10 | 20 | $370 | $14.5K |
Showing 1–10 of 16
Nearby Providers
Other providers in the same ZIP code as Brian Keel, ranked by combined Medicare and Medicaid revenue.
Frequently Asked Questions
References
- 1.Medicare Physician & Other Practitioner by Provider and Service. CMS.gov.Provider-level Medicare Part B utilization and payment data.
- 2.NPPES NPI Registry. CMS.gov.National Provider Identifier registry used for provider enumeration and taxonomy metadata.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.